Section Arrow
NTLA.NASDAQ
- Intellia Therapeutics
Quotes are at least 15-min delayed:2026/11/10 05:55 EST
Pre Market
Last
 12.11
0 (0.00%)
Bid
11.9
Ask
12.24
High 12.11 
Low 11.88 
Volume 618 
Regular Hours (Closed)
Last
 12.11
+0.76 (+6.70%)
Day High 
12.145 
Prev. Close
11.35 
1-M High
13.94 
Volume 
4.17M 
Bid
11.9
Ask
12.24
Day Low
11.15 
Open
11.36 
1-M Low
10.58 
Market Cap 
1.59B 
Currency 美元 
P/E -- 
%Yield -- 
10-SMA 12.08 
20-SMA 11.85 
50-SMA 12.09 
52-W High 18.48 
52-W Low 7.95 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-3.35/-2.11
Enterprise Value
1.66B
Balance Sheet
Book Value Per Share
4.38
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
--
Operating Revenue Per Share
0.38
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
HRTXHeron Therapeutics0.3706+0.0776+26.48%-- 
Pre Market 0.37 -0.0006 -0.16%
EDSAEdesa Biotech2.49+0.35+16.36%-- 
Pre Market 2.3209 -0.1691 -6.79%
ZURAZura Bio Limited1.24-2.85-69.68%-- 
Pre Market 1.22 -0.02 -1.61%
IBRXImmunityBio7.11-1.525-17.66%-- 
Pre Market 7.1286 +0.0186 +0.26%
INOInovio Pharmaceuticals1.51+0.295+24.28%-- 
Pre Market 1.51 0 0.00%
Industry overview quotes are at least 15 minutes delayed (Except Overnight Trading Session)
Business Description
Intellia Therapeutics is a gene-editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. Intellia is focused on using this technology to treat genetically defined diseases. It's evaluating multiple gene editing approaches using in vivo and ex vivo therapies to address diseases with high unmet medical needs, including ATTR amyloidosis, hereditary angioedema, sickle cell disease, and immuno-oncology. Intellia has formed collaborations with several companies to advance its pipeline, including narrow-moat Regeneron and wide-moat Novartis.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.